The global orally disintegrating tablet market size was valued at USD 14.76 billion in 2024 and is projected to grow from USD 16.33 billion in 2025 to USD 28.88 billion by 2033, exhibiting a CAGR of 7 ...

MindMed has dosed the first subject in the Phase III Panorama study of MM120 ODT for the treatment of generalised anxiety ...

The MM120 ODT Phase 3 clinical development program also includes the Voyage study for GAD and the Emerge study for major depressive disorder (MDD). The U.S. Food and Drug Administration has granted ...

Inc. (NASDAQ: MNMD), (the "Company" or "MindMed"), a late-stage clinical biopharmaceutical company developing novel product ...

Biohaven is accused of giving health care providers cash and lavish meals to get them to prescribe Nurtec ODT, a migraine ...

World-recognized brand Pfizer has agreed to a nearly $60 million financial agreement to settle claims that a wholly-owned ...

The US Department of Justice announced Friday that Pfizer has agreed in New York federal court to pay $59.7 million to ...

Biohaven, acquired by Pfizer in 2022, allegedly took doctors to high-end restaurants and paid speaker honoraria for ...

Biohaven wielded meals at high-end restaurants and paid speaking opportunities to induce healthcare providers to prescribe ...

Pfizer has agreed to pay $60 million to resolve allegations brought by the US government that its Biohaven Pharma subsidiary ...

Pfizer will pay nearly $60 million to settle allegations that Biohaven, a company it acquired, paid kickbacks to healthcare ...

Pharmaceutical company Pfizer Incorporated on behalf of its wholly-owned subsidiary Biohaven Pharmaceutical Holding Company Ltd., has agreed ...